Oluwaranti Akiyode
Howard University
12 Papers
22 Citations
Oluwaranti Akiyode is an academic researcher from Howard University. The author has contributed to research in topics: Medicine & Pharmacy. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
Review of Best Practices for Diversity, Equity, and Inclusion Committees Within Colleges of Pharmacy
Srikanth Kolluru,Matthew A. Wanat,Cathy Ficzere,Oluwaranti Akiyode,Stacy L. Haber,Alireza Hayatshahi,David J. Caldwell,Lalitha Raman-Wilms,Krystal L. Edwards +8 more
TL;DR: A review of best practices for diversity, equity, and inclusion (DEI) committees at United States colleges of pharmacy can be found in this article , where the authors provide a review of DEI committee composition, roles, and responsibilities, and their place within a college of pharmacy organizational structure.
Injectable administration privileges among pharmacists in the United States.
TL;DR: Privileges for administering nonvaccine injectable medications among pharmacists in the United States were assessed and Pharmacists in 21 states were found to have privileges for administering injectable medication other than vaccines.
8
Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications
TL;DR: Adequate eye screening is therefore important for the early detection and treatment of visual complications and research has supported the intravitreal administration of steroids, whose anti-inflammatory and antiangiogenic effects are beneficial in diabetic eye complications.
8
Teaching professionalism: A faculty’s perspective
TL;DR: Faculty plays a significant role in the professionalization of pharmacy students through both avoidance of unprofessional behaviors and through consistent demonstration of professional behaviors.
8
Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications.
TL;DR: In the treatment of patients with diabetic macular edema having moderate to severe visual acuity loss, aflibercept outperformed the other 2 anti-VEGF agents (aflibercept vs bevacizumab, P < .001; a flibercept vs ranibizumAB, P = .003).
6